28 results
8-K
EX-99.1
IMPL
Impel Pharmaceuticals Inc
15 Aug 22
Impel PHARMACEUTICALS Announces SECOND Quarter 2022 Financial Results and Provides CORPORATE Update
8:06am
&D spending was primarily due to reduction in Trudhesa clinical expenses as the Phase 3 STOP 301 study was closed, partially offset by an increase
8-K
EX-99.1
IMPL
Impel Pharmaceuticals Inc
14 Nov 22
Impel PHARMACEUTICALS Announces THIRD Quarter 2022 Financial Results and Provides CORPORATE Update
7:55am
expenses as the Phase 3 STOP 301 study was closed, and partially offset by an increase in spend for the clinical development of INP105.
Selling, General
10-Q
3e72n3o5zim3z
7 Jun 21
Quarterly report
7:17am
424B4
ix8pz6hxk4nfdy2qin
10 Sep 21
Prospectus supplement with pricing info
4:01pm
DRS
ulu9nc
25 Aug 21
Draft registration statement
12:00am
DRS/A
ploj zo5nufuih
23 Mar 21
Draft registration statement (amended)
12:00am
S-1
f3j01xhjuy su9
2 Apr 21
IPO registration
3:04pm
424B1
h0nuoau5
23 Apr 21
Prospectus with pricing info
4:01pm
10-K
aqt0zuhpn1goy
29 Mar 22
Annual report
5:09pm
DEF 14A
o2u4xhp7
26 Apr 22
Definitive proxy
4:16pm